학술논문

1387P - Differences in multikinase inhibitors (MKI) toxicity profile according to gender. A pooled analysis of three phase II trials with lenvatinib, pazopanib and sorafenib in patients (pts) with advanced gastroenteropancreatic (GEP) neuroendocrine tumours (NETs)
Document Type
Abstract
Source
In Annals of Oncology October 2019 30 Supplement 5:v567-v567
Subject
Language
ISSN
0923-7534